International Journal of Pharmaceutical Drug Design (IJPDD)
Website: https://ijpdd.org/
ISSN: 2584-2897
Vol. 3, Issue 1, January-June, 2026
Page No.: 188-195

Review

Hydrophilic Polymer-Based Matrix Tablets for Extended Release of Metoprolol succinate: Formulation Strategies, Polymer Selection, Optimization, and Evaluation-A Review

Anurag Singh, Santosh Kumar Mishra*, Narendra Kumar
Department of Pharmacy, Sagar College of Pharmacy, India

Corresponding Author:
Santosh Kumar Mishra

Email:
anuragsingh1572001@gmail.com,
narendra051198@gmail.com

DOI: *10.62896/ijpdd.3.1.23*

Conflict of interest: *NIL*

Article History
Received: 12/02/2026
Accepted: 10/04/2026
Published: 09/05/2026

Abstract:
Metoprolol succinate is a cardioselective β1-adrenergic receptor blocker extensively prescribed for the management of hypertension, angina pectoris, arrhythmias, heart failure, and other cardiovascular disorders. Despite its wide therapeutic use, conventional immediate-release formulations require frequent administration due to relatively short biological half-life and variable plasma concentration profiles, which may result in fluctuations in therapeutic response and reduced patient compliance. Extended-release oral dosage forms have therefore attracted significant pharmaceutical interest because they offer sustained drug release, reduced dosing frequency, improved plasma concentration maintenance, minimized side effects, and enhanced patient adherence. Among various controlled-release technologies, hydrophilic polymer-based matrix tablets remain one of the most widely employed and commercially successful platforms because of their formulation simplicity, cost-effectiveness, scalability, and reliable release modulation characteristics. Hydrophilic polymers such as hydroxypropyl methylcellulose (HPMC), polyethylene oxide (PEO), sodium carboxymethyl cellulose, xanthan gum, and carbopol hydrate upon contact with gastrointestinal fluids, forming a gel barrier that regulates drug diffusion and matrix erosion. The interplay between polymer viscosity, swelling index, hydration rate, tablet porosity, and polymer concentration significantly influences release kinetics and overall dosage performance. This review critically summarizes the pharmaceutical rationale for extended-release matrix tablets of Metoprolol succinate, discusses commonly employed hydrophilic polymers, formulation design strategies, optimization approaches, drug release mechanisms, and evaluation parameters. Special emphasis is placed on polymer selection, matrix integrity, kinetic modeling, and recent advances in smart hydrophilic polymer systems for sustained cardiovascular drug delivery.

Keywords: Metoprolol succinate; Extended release; Hydrophilic polymers; Matrix tablets; HPMC; Controlled release; Drug release kinetics

1. Introduction

Cardiovascular diseases remain one of the leading causes of morbidity and mortality worldwide, necessitating long-term pharmacotherapy for effective disease management **[1]**. Among the commonly prescribed cardiovascular drugs, Metoprolol succinate occupies a prominent therapeutic position because of its selective β1-adrenergic receptor antagonistic activity, which reduces heart rate, myocardial contractility, and

cardiac oxygen demand **[2]**. Clinically, it is widely used in hypertension, chronic heart failure, angina pectoris, myocardial infarction prophylaxis, and supraventricular arrhythmias **[2,3]**.

Although pharmacologically effective, conventional immediate-release dosage forms of Metoprolol succinate may require repeated dosing to maintain therapeutic plasma concentration because of relatively short elimination half-life and rapid systemic clearance **[3]**. Frequent dosing not only increases pill burden but may also contribute to reduced patient adherence, variable plasma concentration peaks and troughs, and higher incidence of dose-related adverse effects such as fatigue, dizziness, and bradycardia **[4]**. These pharmaceutical and clinical limitations have driven substantial interest toward extended-release dosage forms.

Extended-release oral drug delivery systems are specifically designed to release drug gradually over prolonged periods, thereby maintaining plasma concentrations within the therapeutic window for extended durations **[5]**. Compared with immediate-release products, extended-release formulations provide several advantages including reduced dosing frequency, improved compliance, minimized plasma fluctuation, lower incidence of concentration-dependent side effects, and potentially improved therapeutic efficacy **[5,6]**. Among the numerous controlled-release technologies investigated, matrix tablet systems remain among the most practical and industrially feasible dosage forms.

Hydrophilic polymer-based matrix tablets have gained exceptional importance because of their simple manufacturing process, broad excipient compatibility, predictable release modulation, and adaptability for drugs with varying physicochemical properties **[6,7]**. Upon exposure to aqueous gastrointestinal fluid, hydrophilic polymers rapidly hydrate and swell, producing a viscous gel layer around the tablet core. This gel barrier acts as a dynamic diffusion membrane that regulates drug release through hydration-controlled diffusion, matrix swelling, and gradual erosion mechanisms **[7,8]**. The thickness, strength, and integrity of this hydrated gel layer largely determine release kinetics. For Metoprolol succinate, which exhibits favorable aqueous solubility and suitable pharmacokinetic properties for sustained release formulation, hydrophilic polymer matrix tablets provide an effective platform for extended delivery **[8]**. The use of polymers such as HPMC of varying viscosity grades, polyethylene oxide, carbopol, sodium alginate, and natural gums enables modulation of release profile according to therapeutic requirements **[9,10]**. Furthermore, modern formulation optimization approaches such as factorial design, response surface methodology, and Quality by Design (QbD) frameworks have significantly improved formulation reproducibility and industrial scalability **[11]**.

Therefore, this review focuses on formulation strategies, polymer science, optimization approaches, characterization methods, and future opportunities in hydrophilic polymer-based matrix tablets of Metoprolol succinate for extended oral delivery.

2. Rationale for Extended-Release Matrix Tablets of Metoprolol succinate

Extended-release oral dosage forms are designed to maintain therapeutic drug concentrations in systemic circulation for prolonged durations, thereby reducing dosing frequency and improving pharmacotherapeutic outcomes **[12,13]**. In the case of Metoprolol succinate, extended-release formulations are particularly valuable because cardiovascular disease management generally requires chronic daily therapy, where improved adherence significantly influences long-term clinical outcomes **[14]**. Frequent administration of immediate-release formulations may lead to poor compliance, fluctuating plasma concentrations, and inconsistent β1-receptor blockade, which may compromise therapeutic efficacy **[15]**.

Pharmacokinetically, Metoprolol succinate possesses characteristics favorable for sustained-release dosage design, including adequate aqueous solubility, acceptable gastrointestinal permeability, and predictable absorption kinetics **[16]**. Controlled-release systems aim to achieve gradual drug liberation over 12–24 hours, thereby maintaining plasma concentration within the therapeutic window while minimizing peak-related adverse effects such as hypotension, dizziness, and bradycardia **[17]**. Furthermore, extended-release products often improve tolerability by reducing abrupt systemic exposure and smoothing concentration–time fluctuations.

Matrix tablets remain among the most industrially practical extended-release dosage forms because of ease of manufacturing, reduced processing

complexity, lower cost, and scalability compared with coated reservoir systems or osmotic pump technologies **[18]**. Drug release from matrix tablets depends on the dynamic interaction among hydration, swelling, gel layer formation, diffusion, erosion, and matrix porosity. Proper optimization of polymer grade, polymer concentration, excipient selection, and compression characteristics is therefore essential to achieve predictable release kinetics **[19]**.

For highly water-soluble drugs such as Metoprolol succinate, controlling burst release is one of the major formulation challenges. Hydrophilic polymer systems effectively address this issue by rapidly forming a viscous gel barrier upon hydration, thereby limiting immediate drug diffusion and enabling controlled sustained release over extended periods **[20]**.

3. Hydrophilic Polymers in Matrix Tablet Design

Hydrophilic polymers are the cornerstone of swellable matrix tablet technology because of their ability to absorb water, hydrate rapidly, swell, and form a gel barrier that modulates drug diffusion and matrix erosion **[21]**. Upon oral administration, gastrointestinal fluid penetrates the tablet surface, causing polymer hydration and chain relaxation. This leads to formation of a gelatinous outer layer that acts as a diffusional barrier to drug release. As hydration continues, inner polymer layers swell progressively while outer gel layers slowly erode, producing sustained and predictable drug release kinetics **[22]**.

Among synthetic hydrophilic polymers, **hydroxypropyl methylcellulose (HPMC)** remains the most widely used matrix-forming polymer due to excellent compressibility, non-toxicity, pH-independent swelling behavior, reproducible hydration characteristics, and broad regulatory acceptance **[23]**. Different viscosity grades of HPMC, such as K4M, K15M, and K100M, enable precise modulation of release kinetics according to therapeutic need. Higher viscosity grades produce stronger gel layers and slower drug diffusion.

Polyethylene oxide (PEO) is another highly effective hydrophilic polymer characterized by rapid swelling, high molecular weight, strong gel integrity, and robust sustained-release performance **[24]**. PEO often demonstrates superior swelling capacity compared with cellulose derivatives and is particularly useful in high-drug-load formulations. However, polymer oxidation sensitivity and processing considerations may affect long-term stability.

Carbopol, a crosslinked polyacrylic acid polymer, provides excellent hydration and high viscosity at relatively low concentrations. Its strong swelling behavior enhances gel barrier strength and contributes to prolonged release, though excessive carbopol concentration may adversely affect tablet hardness and release reproducibility **[25]**. Natural hydrophilic polymers such as xanthan gum, guar gum, sodium alginate, locust bean gum, and modified starches have also gained increasing interest because of biodegradability, cost-effectiveness, and favorable release-retarding properties **[26]**.

Polymer blends are frequently employed to combine the advantages of different materials. For example, HPMC–xanthan gum combinations may improve matrix robustness, while HPMC–carbopol systems may strengthen gel structure and reduce burst release **[27]**. Such combinations allow formulation scientists to optimize swelling kinetics, erosion rate, diffusional resistance, and tablet mechanical properties simultaneously.

Table 1. Common Hydrophilic Polymers Used in Extended-Release Matrix Tablets

Polymer	Type	Major Property	Effect on Drug Release	Limitations
Hypromellose (HPMC)	Semi-synthetic cellulose ether	Strong hydration and gel formation	Excellent sustained release control	High viscosity may slow compression
Polyethylene Oxide (PEO)	Synthetic polymer	Rapid swelling, high gel strength	Prolonged release	Oxidative sensitivity
Carbopol	Crosslinked acrylic polymer	High viscosity at low concentration	Strong retardation effect	May affect compressibility
Xanthan Gum	Natural polysaccharide	High swelling, biodegradable	Sustained release and matrix integrity	Batch variability

Sodium Alginate	Natural polymer	pH-responsive swelling	Controlled release modulation	Sensitive to ionic strength
Guar Gum	Natural galactomannan	High viscosity	Economical release retarder	Microbial stability concerns



4. Optimization Strategies in Hydrophilic Polymer-Based Matrix Tablet Development

The successful design of hydrophilic polymer-based matrix tablets for extended release of Metoprolol succinate depends on systematic optimization of formulation variables that directly influence matrix hydration, gel integrity, diffusional resistance, erosion kinetics, and overall drug release behavior [28,29]. Because matrix tablet performance is governed by multiple interacting factors, modern pharmaceutical development increasingly relies on statistical optimization approaches rather than empirical trial-and-error formulation methods [30].

Among the most critical formulation variables is polymer concentration, which strongly determines gel barrier thickness and matrix robustness. Increasing polymer concentration generally slows drug release by producing a denser and more viscous hydrated barrier, reducing diffusion rate and delaying erosion [31]. However, excessively high polymer loading may compromise compressibility, increase tablet size, and negatively influence patient acceptability. Therefore, polymer content must be optimized carefully according to drug dose and desired release duration.

Polymer viscosity grade also plays a major role in release modulation. Higher viscosity grades of HPMC (e.g., K100M) produce stronger gel layers and slower diffusion than lower viscosity grades (e.g., K4M), allowing fine tuning of release kinetics [32]. Blending viscosity grades is a common strategy to achieve balanced hydration and release control. Similarly, polymer combinations such as HPMC–PEO, HPMC–carbopol, and HPMC–natural gum systems are often optimized to improve matrix integrity, minimize burst release, and enhance robustness under variable gastrointestinal conditions [33].

Other important formulation variables include drug-to-polymer ratio, particle size of excipients, tablet hardness, compression force, lubricant concentration, and diluent selection, each of which can affect porosity, wetting behavior, and release reproducibility [34]. For highly water-soluble drugs such as Metoprolol succinate, inclusion of hydrophobic modifiers or polymer combinations is sometimes employed to further retard initial diffusion and control burst release [35].

Modern optimization approaches such as factorial design, response surface methodology (RSM), Box–Behnken design, and Quality by Design (QbD) frameworks provide systematic evaluation of formulation variables and their interactions [30,36]. These tools enable prediction of optimum polymer concentration, viscosity grade, excipient composition, and compression parameters to achieve target release profiles while maintaining tablet quality and manufacturability.

5. Evaluation Parameters for Extended-Release Matrix Tablets

Comprehensive evaluation of hydrophilic matrix tablets is essential to ensure formulation quality, reproducibility, and controlled-release performance **[37]**. Evaluation begins with **pre-compression parameters** such as bulk density, tapped density, Hausner ratio, Carr's compressibility index, and angle of repose, which provide insight into powder flow and compressibility characteristics important for large-scale manufacturing **[38]**.

Following compression, tablets are evaluated for **physical quality attributes** including thickness, hardness, friability, weight variation, and drug content uniformity. Adequate hardness ensures mechanical stability during packaging and transport, while low friability indicates resistance to abrasion and handling stress **[39]**. Uniform drug distribution is essential to maintain dose consistency and therapeutic reliability.

For hydrophilic matrix systems, **swelling index** is a critical parameter because polymer hydration and gel formation determine release kinetics. Swelling studies help quantify water uptake capacity and matrix expansion behavior over time **[40]**. **Matrix erosion studies** are equally important because erosion contributes significantly to drug release, particularly in swellable and biodegradable polymer systems.

The most important performance evaluation remains **in vitro dissolution testing**, typically performed using standardized dissolution apparatus in simulated gastrointestinal media **[41]**. Release data are commonly analyzed using kinetic models such as **zero-order**, **first-order**, **Higuchi**, **Hixson–Crowell**, and **Korsmeyer–Peppas** equations to understand the dominant release mechanism **[42]**. For hydrophilic matrices, release is often governed by anomalous transport involving both diffusion and polymer erosion.

Advanced characterization techniques including **scanning electron microscopy (SEM)**, **differential scanning calorimetry (DSC)**, **Fourier transform infrared spectroscopy (FTIR)**, and **X-ray diffraction (XRD)** provide additional insight into matrix morphology, drug–polymer compatibility, crystallinity, and structural stability **[43]**. Stability studies under accelerated and long-term storage conditions further confirm formulation robustness and shelf-life suitability **[44]**.

Table 2. Key Optimization Variables and Evaluation Parameters in Hydrophilic Matrix Tablets

Category	Parameter	Significance	Desired Outcome
Formulation Variable	Polymer concentration	Controls gel barrier strength	Optimized sustained release
	Polymer viscosity	Determines swelling and diffusion	Controlled release profile
	Drug:polymer ratio	Influences burst release	Balanced matrix integrity
Compression Variable	Hardness	Mechanical strength	Adequate tablet robustness
	Compression force	Affects porosity	Uniform compactness
Physical Evaluation	Friability	Handling resistance	<1%
	Drug content	Dose uniformity	95–105%
Functional Evaluation	Swelling index	Gel formation ability	Controlled hydration
	Erosion index	Matrix integrity	Predictable erosion
Release Testing	Dissolution profile	Therapeutic release duration	12–24 h sustained release
Kinetic Modeling	Release mechanism	Mechanistic understanding	Diffusion / erosion controlled
Stability	Shelf-life	Long-term quality	Stable formulation



6. Future Perspectives

Hydrophilic polymer-based matrix tablets remain one of the most robust and industrially accepted platforms for sustained oral drug delivery; however, future developments are expected to focus on precision-controlled release systems, multifunctional polymer networks, and patient-centered formulation design [45,46]. For highly prescribed cardiovascular agents such as Metoprolol succinate, next-generation matrix systems may move beyond simple sustained release toward more programmable release kinetics aligned with circadian rhythm, disease severity, and individualized therapeutic needs.

One promising direction is the use of polymer blending and hybrid matrix technologies, combining hydrophilic polymers with hydrophobic excipients, biodegradable biopolymers, or nanostructured carriers to achieve more precise control over burst release, swelling behavior, and long-term matrix integrity [47]. Multi-polymer systems may also improve compression behavior, reduce tablet variability, and provide greater flexibility in tailoring release kinetics.

Another important advancement is the development of stimuli-responsive polymer matrices that respond to pH, ionic strength, gastrointestinal motility, or enzymatic activity [48]. These "smart matrices" may enable site-specific drug release, improved therapeutic precision, and adaptive release behavior under changing physiological conditions. Incorporation of nanomaterials, microporous carriers, and drug-loaded nanoparticles within hydrophilic matrices is also emerging as a strategy to improve drug distribution and kinetic control.

Modern pharmaceutical development increasingly incorporates Quality by Design (QbD), process analytical technology (PAT), and machine learning-assisted formulation modeling to improve manufacturing reproducibility and reduce development timelines [49]. Predictive computational models can estimate release kinetics, swelling behavior, and matrix erosion characteristics based on polymer properties, thereby minimizing extensive experimental screening.

Additionally, future work may emphasize continuous manufacturing technologies, 3D printing of matrix tablets, and personalized dosage design, enabling tailored release profiles for individual patient needs [50]. Such innovations may substantially improve adherence and therapeutic outcomes in chronic cardiovascular disease management.

Overall, the future of hydrophilic matrix tablets lies in integrating polymer science, material engineering, computational pharmaceutics, and patient-focused drug delivery design.

7. Conclusion

Hydrophilic polymer-based matrix tablets remain among the most effective and practical extended-release oral dosage platforms for delivering Metoprolol succinate in chronic cardiovascular therapy. Their formulation simplicity, cost-effectiveness, scalability, and predictable release-modulating behavior make them highly attractive for both pharmaceutical development and commercial manufacturing [6,28].

This review demonstrates that hydrophilic polymers such as HPMC, polyethylene oxide, carbopol, sodium alginate, xanthan gum, and polymer blends play a central role in regulating matrix hydration, gel formation, diffusional resistance, and erosion kinetics, thereby determining overall drug release behavior [23–27]. Appropriate optimization of polymer concentration, viscosity grade, compression characteristics, and excipient composition is essential to achieve robust extended-release performance.

Modern optimization strategies based on Design of Experiments (DoE) and Quality by Design (QbD) have significantly enhanced formulation understanding, reproducibility, and industrial scalability [30,49]. Furthermore, advanced characterization techniques—including swelling studies, dissolution modeling, morphological analysis, compatibility assessment, and stability testing—provide critical insight into formulation quality and therapeutic performance [40–44].

Future innovations involving smart polymers, hybrid matrix systems, computational modeling, and personalized manufacturing approaches are expected to further improve the performance of extended-release hydrophilic matrix tablets. Overall, hydrophilic polymer-based matrix systems continue to offer a scientifically sound and technologically adaptable platform for optimized sustained delivery of Metoprolol succinate.

Acknowledgment

The authors acknowledge the Department of Pharmacy, Sagar College of Pharmacy, for academic

support and encouragement in preparation of this review article.

Conflict of Interest

The authors declare no conflict of interest.

References

1. World Health Organization. Cardiovascular diseases: global burden and management reports.
2. Frishman WH. Beta-adrenergic blockers: pharmacology and clinical applications. *J Clin Hypertens*. 2003;5(6):429–440.
3. Sweetman SC. *Martindale: The Complete Drug Reference*. 38th ed. Pharmaceutical Press; 2014.
4. Brahmankar DM, Jaiswal SB. *Biopharmaceutics and Pharmacokinetics: A Treatise*. Vallabh Prakashan; 2016.
5. Colombo P, Bettini R, Santi P, Peppas NA. Swellable matrices for controlled drug delivery. *J Control Release*. 2000;39:231–237.
6. Siepmann J, Peppas NA. Hydrophilic matrices for controlled drug delivery. *Adv Drug Deliv Rev*. 2012;64:163–174.
7. Ford JL. Design and evaluation of hydroxypropyl methylcellulose matrix tablets. *Int J Pharm*. 1999;179(2):209–228.
8. Nokhodchi A, Raja S, Patel P, Asare-Addo K. The role of oral controlled-release matrix tablets in modern pharmaceutics. *Biomed Res Int*. 2012;2012:816891.
9. Li CL, Martini LG, Ford JL, Roberts M. The use of hypromellose in oral sustained-release matrix tablets. *J Pharm Pharmacol*. 2005;57(5):533–546.
10. Alderman DA. A review of cellulose ethers in hydrophilic matrices. *Int J Pharm Tech Prod Mfr*. 1984;5:1–9.
11. Yu LX. Pharmaceutical quality by design: product and process understanding. *Pharm Res*. 2008;25(4):781–791.
12. Robinson JR, Lee VHL. Controlled Drug Delivery: Fundamentals and Applications. 2nd ed. Marcel Dekker; 1987.
13. Wise DL. Handbook of Pharmaceutical Controlled Release Technology. CRC Press; 2000.
14. Frishman WH. Cardiovascular pharmacotherapy and compliance considerations. Cardiol Rev. 2002;10(4):230–238.
15. Sweetman SC. Martindale: The Complete Drug Reference. 38th ed. Pharmaceutical Press; 2014.
16. Brahmankar DM, Jaiswal SB. Biopharmaceutics and Pharmacokinetics. Vallabh Prakashan; 2016.
17. Rowe RC, Sheskey PJ, Quinn ME. Handbook of Pharmaceutical Excipients. 7th ed. Pharmaceutical Press; 2012.
18. Banker GS, Rhodes CT. Modern Pharmaceutics. 4th ed. CRC Press; 2002.
19. Nokhodchi A, Raja S, Patel P, Asare-Addo K. Oral controlled-release matrix systems: formulation principles. Biomed Res Int. 2012;2012:816891.
20. Siepmann J, Peppas NA. Modeling of drug release from hydrophilic matrices. Adv Drug Deliv Rev. 2012;64:163–174.
21. Colombo P, Bettini R, Santi P, Peppas NA. Swellable matrices for controlled drug delivery. J Control Release. 2000;39:231–237.
22. Ford JL. Design and evaluation of hydrophilic matrix tablets. Int J Pharm. 1999;179(2):209–228.
23. Li CL, Martini LG, Ford JL, Roberts M. The use of HPMC in oral sustained-release matrix tablets. J Pharm Pharmacol. 2005;57(5):533–546.
24. Crowley MM, Schroeder B, Fredersdorf A, et al. Physicochemical properties of polyethylene oxide in matrix tablets. Pharm Dev Technol. 2004;9(2):129–138.
25. Singh B, Kim KH. Carbopol-based matrix systems in oral controlled release. Drug Dev Ind Pharm. 2000;26(6):607–617.
26. Patel VF, Patel NM. Natural polymers in matrix tablet design. Drug Dev Ind Pharm. 2007;33(8):831–847.
27. Dash S, Murthy PN, Nath L, Chowdhury P. Polymer blending strategies for sustained-release matrices. Acta Pol Pharm. 2010;67(3):217–223.
28. Siepmann J, Peppas NA. Hydrophilic matrices in controlled drug delivery: design principles. Adv Drug Deliv Rev. 2012;64:163–174.
29. Nokhodchi A, Raja S, Patel P, Asare-Addo K. Oral controlled-release matrix tablets. Biomed Res Int. 2012;2012:816891.

30. Yu LX. Pharmaceutical quality by design: product understanding and process control. Pharm Res. 2008;25(4):781–791.
31. Ford JL. Matrix tablet swelling and gel layer behavior. Int J Pharm. 1999;179(2):209–228.
32. Li CL, Martini LG, Ford JL, Roberts M. Hypromellose viscosity grade effects on sustained release matrices. J Pharm Pharmacol. 2005;57(5):533–546.
33. Dash S, Murthy PN, Nath L, Chowdhury P. Polymer blending in sustained-release matrix systems. Acta Pol Pharm. 2010;67(3):217–223.
34. Banker GS, Rhodes CT. Modern Pharmaceutics. 4th ed. CRC Press; 2002.
35. Crowley MM, Schroeder B, Fredersdorf A, et al. Controlled-release polymer matrices for water-soluble drugs. Pharm Dev Technol. 2004;9(2):129–138.
36. Myers RH, Montgomery DC, Anderson-Cook CM. Response Surface Methodology. 4th ed. Wiley; 2016.
37. Lachman L, Lieberman HA, Kanig JL. The Theory and Practice of Industrial Pharmacy. CBS Publishers; 2013.
38. Aulton ME, Taylor KMG. Aulton's Pharmaceutics: The Design and Manufacture of Medicines. 5th ed. Elsevier; 2018.
39. United States Pharmacopeia (USP). Tablet quality evaluation standards. Current edition.
40. Colombo P, Bettini R, Santi P, Peppas NA. Swelling-controlled drug release matrices. J Control Release. 2000;39:231–237.
41. Dressman JB, Krämer J. Pharmaceutical Dissolution Testing. Taylor & Francis; 2005.
42. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of drug release from polymeric systems. Int J Pharm. 1983;15(1):25–35.
43. Hancock BC, Zografi G. Characterization of pharmaceutical solids and matrix systems. J Pharm Sci. 1997;86(1):1–12.
44. International Council for Harmonisation. Stability Testing of New Drug Products (ICH Q1A)
45. Peppas NA, Bures P, Leobandung W, Ichikawa H. Hydrogels in pharmaceutical formulations and controlled drug delivery. Eur J Pharm Biopharm. 2000;50(1):27–46.
46. Siepmann J, Siepmann F. Mathematical modeling of drug delivery from matrix systems. Int J Pharm. 2008;364(2):328–343.
47. Dash S, Murthy PN, Nath L, Chowdhury P. Polymer blending strategies in controlled-release matrix formulations. Acta Pol Pharm. 2010;67(3):217–223.
48. Bawa P, Pillay V, Choonara YE, du Toit LC. Stimuli-responsive polymers in controlled drug delivery. Biomed Mater. 2009;4(2):022001.
49. Yu LX. Pharmaceutical quality by design: product and process understanding. Pharm Res. 2008;25(4):781–791.
50. Norman J, Madurawe RD, Moore CMV, Khan MA, Khairuzzaman A. A new chapter in pharmaceutical manufacturing: 3D printed drug products. Adv Drug Deliv Rev. 2017;108:39–50.

*****